Entera Appoints Global Pharmaceutical Leader Riccardo Paolo Camisasca, M.D., as Chief Medical Officer Ahead of Planned EB613 Phase 3 Initiation

Go back to Entera Appoints Global Pharmaceutical Leader Riccardo Paolo Camisasca, M.D., as Chief Medical Officer Ahead of Planned EB613 Phase 3 Initiation
Entrx Corporation (NASDAQ: ENTX) Delayed: 2.98 -0.07 (2.3%)
Previous Close $3.05    52 Week High $0.30 
Open $3.01    52 Week Low $0.10 
Day High $3.03    P/E N/A 
Day Low $2.90    EPS $0.00 
Volume 375,916